Baidu
map

Cell Metab:改善睡眠的保健品可能增加糖尿病患病风险

2016-05-17 佚名 生物谷

近日,来自瑞典隆德大学糖尿病中心的研究人员在国际学术期刊Cell Metabolism上发表了一项最新研究进展,他们发现胰岛细胞中褪黑素信号增强会降低胰岛素分泌,可能导致高血糖症并增加2型糖尿病患病风险。   目前2型糖尿病逐渐成为一种全球性公共健康问题,其流行趋势越来越严重。全基因组关联性分析已经发现了超过100个与糖尿病有关的变异基因,其中包括一个比较常见的变异基因--MTN

近日,来自瑞典隆德大学糖尿病中心的研究人员在国际学术期刊Cell Metabolism上发表了一项最新研究进展,他们发现胰岛细胞中褪黑素信号增强会降低胰岛素分泌,可能导致高血糖症并增加2型糖尿病患病风险。
 
目前2型糖尿病逐渐成为一种全球性公共健康问题,其流行趋势越来越严重。全基因组关联性分析已经发现了超过100个与糖尿病有关的变异基因,其中包括一个比较常见的变异基因--MTNR1B(褪黑素受体1b)。MTNR1B能够增加细胞对褪黑素的敏感性,但该基因在胰岛细胞中发挥什么样的作用一直没有得到研究。
 
在这项研究中,研究人员对携带MTNR1B基因变异的病人数据进行了分析,其中既包括携带一个基因变异的病人,也包括携带两个基因变异的病人。存在两个基因变异的病人其胰岛细胞内MTNR1B基因表达更强,对褪黑素也更加敏感。
 
研究人员发现,在胰岛素分泌细胞中,褪黑素能够降低cAMP水平,过表达MTNR1B会进一步增强褪黑素介导的对胰岛素释放的抑制作用。而在小鼠模型中干扰该受体表达则会促进胰岛素的分泌。
 
研究人员又对23名携带MTNR1B基因变异的参与者和22名不携带MTNR1B基因变异的参与者进行研究,要求他们在三个月内,每天睡前服用4毫克褪黑素。最后结果显示,不携带基因变异的参与者其胰岛素分泌水平比基因变异携带者高出3倍。
 
褪黑素本身能够帮助身体调整生物钟,帮助改善睡眠。这项研究并非表明携带MTNR1B基因变异的人偶尔服用了褪黑素就一定会对身体造成损害。研究人员表示,目前这些结果还没有得到大规模验证,但仍提示我们长期服用褪黑素或许并非完全无害。
 
原始出处:
 
Tiinamaija Tuomi12, Cecilia L.F. Nagorny12, Pratibha Singh12, Hedvig Bennet, Qian Yu, Ida Alenkvist, Bo Isomaa, Bjarne ?stman, Johan S?derstr?m, Anu-Katriina Pesonen, Silja Martikainen, Katri R?ikk?nen, Tom Forsén, Liisa Hakaste, Peter Almgren, Petter Storm, Olof Asplund, Liliya Shcherbina, Malin Fex, Jo?o Fadista, Anders Tengholm, Nils Wierup, Leif Groop13, Hindrik Mulder.Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes Cell Metab 2016
 
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959637, encodeId=0f0e195963e76, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 29 06:29:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887521, encodeId=90f4188e52155, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Jun 08 20:29:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869380, encodeId=c06918693806f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 08 10:29:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895897, encodeId=e3fd189589e1b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Feb 22 04:29:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281740, encodeId=dfd01281e407d, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 19 11:29:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-05-29 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959637, encodeId=0f0e195963e76, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 29 06:29:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887521, encodeId=90f4188e52155, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Jun 08 20:29:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869380, encodeId=c06918693806f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 08 10:29:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895897, encodeId=e3fd189589e1b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Feb 22 04:29:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281740, encodeId=dfd01281e407d, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 19 11:29:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-06-08 guojianrong
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959637, encodeId=0f0e195963e76, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 29 06:29:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887521, encodeId=90f4188e52155, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Jun 08 20:29:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869380, encodeId=c06918693806f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 08 10:29:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895897, encodeId=e3fd189589e1b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Feb 22 04:29:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281740, encodeId=dfd01281e407d, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 19 11:29:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959637, encodeId=0f0e195963e76, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 29 06:29:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887521, encodeId=90f4188e52155, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Jun 08 20:29:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869380, encodeId=c06918693806f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 08 10:29:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895897, encodeId=e3fd189589e1b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Feb 22 04:29:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281740, encodeId=dfd01281e407d, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 19 11:29:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2017-02-22 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959637, encodeId=0f0e195963e76, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 29 06:29:00 CST 2016, time=2016-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887521, encodeId=90f4188e52155, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Jun 08 20:29:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869380, encodeId=c06918693806f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 08 10:29:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895897, encodeId=e3fd189589e1b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Feb 22 04:29:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281740, encodeId=dfd01281e407d, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 19 11:29:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]

相关资讯

JAMA Inter Med:经常感冒?可能是睡眠不足惹的祸!

“吃好、睡好、身体好!”睡眠越来越被认为是维持身体健康的重要决定因素。美国国立卫生研究院(NIH)推荐,成年人睡眠理想时长为7-8个小时。然而,随着现代社会工作和生活的节奏越来越快、压力越来越大,睡眠障碍和睡眠不足正在悄悄地夺走许多人的健康。在美国,约5000-7000万人要么存在睡眠障碍,要么经常性睡眠不足。2016年4月11日发表于美国医学会《JAMA内科学》的一项最新研究称,每晚睡眠不超过五

Business insider:睡觉时能学到的4件事

  (图片摘自www.sciencealert.com) 今天晚上睡觉以前,你不妨放一本书在枕头下面。这样的话,明天早上一早醒来你就会记得书里的内容了。 以上内容是胡扯。不过,睡眠时我们确实也能学到一些东西。 1.学习外语单词 在最近的一项试验中,科学家们训练德国人说荷兰语。首先从一些基本的单词开始,之后这些人被安排去睡觉。 当他们睡着时,科学家们在一组志愿者的周围循环播放

Cell:挑战常规!睡眠抑制大脑自我再平衡!

人类和其他动物为何睡眠是生理学剩下的深层奥秘之一。神经科学的主导理论是睡眠是大脑“下线”时回放记忆以便更好地编码它们(“记忆巩固”)。另一种主导的竞争性理论就是睡眠在大脑网络的再平衡(re-balancing)中发挥着重要作用,而在清醒(waking,也译作醒着,或者唤醒)时的学习期间,大脑网络受到扰乱。大脑活动的这种“再平衡”涉及稳态可塑性(ho

JAMA Pediatr:青少年睡眠不足可能会增加糖尿病风险

新研究表明,青少年夜间睡眠不足八小时,更有可能出现上腹部脂肪堆积和胰岛素敏感性的下降,进而导致2型糖尿病。巴西圣保罗坎皮纳斯大学代谢和糖尿病调查研究实验室的Bruno Geloneze博士说:“先前有研究表明,睡眠不足会增加心血管疾病的危险因素,包括肥胖和糖尿病发病率的增加。”他说:“我们研究表明,胰岛素抵抗的增加是独立于肥胖的存在,睡眠不足与代谢紊乱之间可能存在潜在相关性。”胰腺产生的胰岛素调控

科学家解密:为什么在新环境**晚往往睡眠不好?

自从人类开始睡在巢穴便出现第一晚效应(FNE),这已经成为人类的习惯和经验,但研究人员并不了解其内在机制。此外,考虑到FNE的存在,他们在进行实验的时候往往会弃去第一晚的研究数据,因为他们知道这个数据并不具有准确性。以Yuka Sasaki为首的布朗大学研究人员开始调查这一现象的内在机制。他们试图探究FNE的发生对机体的保护作用,使用先进的神经影像技术对睡眠中的大脑采取快照,并收集民众处于新环境第

Neurology:创伤性脑损伤发生18月后,患者依旧存在睡眠问题!

目的本研究为前瞻性对照临床试验和生理学研究,主要研究内容是创伤性脑损伤后患者出现的慢性睡眠紊乱。 方法研究人员选取了140名首次发生急性创伤性脑损伤的患者,严重程度各有不同,其中包括60例前瞻性随访调查。患者若在出现脑损伤之前还患有其他神经或系统性疾病、出现药物滥用史及精神疾病则不参与研究。创伤18个月后,研究人员对31个参与者的睡眠状况进行了详细的评估。对照组民众为年龄、性别、睡眠连续的健康民众

Baidu
map
Baidu
map
Baidu
map